Biocompatibility of Dental Materials - A Review

L, Gokul G; Lakshmi, T; R, Don K

doi:10.26452/ijrps.v11ispl3.3487

Cited by 1 publication

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential toxicity of materials to be in contact with biological interfaces is a great matter of concern in diverse clinical fields. − In this context, novel biodegradable and biomimetic materials are under continuous exploration, tailoring, and development to avoid undesired side damage in the patient. − Aiming at the delivery of bioactive proteins, including drugs and antigens, protein-based constructs benefit from the intrinsic lack of toxicity of polypeptides as universal biomacromolecules. This is in addition to their functional and structural versatility that can be adjusted by rather simple genetic engineering. − Among emerging protein materials, those based on self-assembling architectonic principles allow the fabrication of supramolecular entities with increasing levels of complexity from nano to microscales.…”

Section: Introductionmentioning

confidence: 99%

“…The potential toxicity of materials to be in contact with biological interfaces is a great matter of concern in diverse clinical fields. 1 − 8 In this context, novel biodegradable and biomimetic materials are under continuous exploration, tailoring, and development to avoid undesired side damage in the patient. 9 − 13 Aiming at the delivery of bioactive proteins, including drugs and antigens, protein-based constructs benefit from the intrinsic lack of toxicity of polypeptides as universal biomacromolecules.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins

Álamo,

Parladé,

Favaro

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Among bio-inspired protein materials, secretory protein microparticles are of clinical interest as self-contained, slow protein delivery platforms that mimic secretory granules of the human endocrine system, in which the protein is both the drug and the scaffold. Upon subcutaneous injection, their progressive disintegration results in the sustained release of the building block polypeptides, which reach the bloodstream for systemic distribution and subsequent biological effects. Such entities are easily fabricated in vitro by Zn-assisted cross-molecular coordination of histidine residues. Using cationic Zn for the assembly of selected pure protein species and in the absence of any heterologous holding material, these granules are expected to be nontoxic and therefore adequate for different clinical uses. However, such presumed biosafety has not been so far confirmed and the potential protein dosage threshold not probed yet. By selecting the receptor binding domain (RBD) from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein as a model protein and using a mouse lab model, we have explored the toxicity of RBD-made secretory granules at increasing doses up to ∼100 mg/kg of animal weight. By monitoring body weight and biochemical blood markers and through the histological scrutiny of main tissues and organs, we have not observed systemic toxicity. Otherwise, the bioavailability of the material was demonstrated by the induction of specific antibody responses. The presented data confirm the intrinsic biosafety of artificial secretory granules made by recombinant proteins and prompt their further clinical development as self-contained and dynamic protein reservoirs.

show abstract